# A Study to Evaluate the Efficacy and Safety of Ansofaxine Hydrochloride Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)

> **NCT04853407** · PHASE3 · COMPLETED · sponsor: **Luye Pharma Group Ltd.** · enrollment: 558 (actual)

## Conditions studied

- Major Depressive Disorder (MDD)

## Interventions

- **DRUG:** LY03005 extended-release tablet
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04853407
- **Lead sponsor:** Luye Pharma Group Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-05
- **Primary completion:** 2020-12-24
- **Final completion:** 2020-12-24
- **Target enrollment:** 558 (ACTUAL)
- **Last updated:** 2021-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04853407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04853407, "A Study to Evaluate the Efficacy and Safety of Ansofaxine Hydrochloride Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04853407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*